NCT00384150View on ClinicalTrials.gov

Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)

PHASE3TerminatedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Lymphoma, Non-Hodgkin's

Interventions

DRUG

galiximab in combination with rituximab

galiximab (500 mg/m2 IV) in combination with rituximab (375 mg/m2 IV)once weekly for 4 weeks.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Biogen

INDUSTRY